The dopamine stabilizers (S)-(-)-(3-methanesulfonyl-phenyl)-1-propyl-piperidine [(-)-OSU6162] and 4-(3-methanesulfonylphenyl)-1-propyl-piperidine (ACR16) show high in vivo D2 receptor occupancy, antipsychotic-like efficacy, and low potential for motor side effects in the rat

The Journal of Pharmacology and Experimental Therapeutics
Sridhar NatesanShitij Kapur

Abstract

"Dopamine stabilizers" are a new class of compounds that have the ability to reverse both hypo- as well as hyperdopaminergia in vivo. This class, exemplified by the phenylpiperidines (S)-(-)-3-(3-methanesulfonyl-phenyl)-1-propyl-piperidine [(-)-OSU6162] and 4-(3-methanesulfonyl-phenyl)-1-propyl)-piperidine [ACR16] although lacking high in vitro binding affinity for dopamine D2 receptor [(-)-OSU6162, Ki = 447 nM; ACR16, Ki > 1 microM], shows functional actions, suggestive of their interaction. Hence, we evaluated in vivo D2 occupancy of these agents in rats and correlated it to observed effects in a series of behavioral, neurochemical, and endocrine models relevant to the dopamine system and antipsychotic effect. Both (-)-OSU6162 and ACR16 showed robust dose-dependent striatal D2 occupancy with ED50 values of 5.27 and 18.99 mg/kg s.c., respectively, and functional assays showed no partial agonism. Over an occupancy range of 37 to 87% (3-60 mg/kg) for (-)-OSU6162 and 35 to 74% (10-60 mg/kg) for ACR16, we observed both inhibitory (amphetamine-induced locomotor activity) and stimulatory effects (in habituated rats). Haloperidol, over a similar occupancy range (33-78%), potently inhibited psychostimulant activity and induced catalep...Continue Reading

References

Aug 2, 1988·European Journal of Pharmacology·S HjorthA Carlsson
Aug 1, 1985·Journal of Medicinal Chemistry·A M JohanssonB Andersson
Feb 26, 2000·European Journal of Pharmacology·A EkesboJ Tedroff
Oct 30, 2001·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·M L WadenbergS Kapur
Feb 28, 2003·The Journal of Pharmacology and Experimental Therapeutics·Shitij KapurJose N Nobrega
Jul 16, 2003·European Journal of Pharmacology·Satoru NakaiTetsuro Kikuchi
Jan 1, 1961·Archives of Neurology·A BARBEAU
Oct 29, 2003·The Neuroscientist : a Review Journal Bringing Neurobiology, Neurology and Psychiatry·Anissa Abi-Dargham, Holly Moore
Jan 8, 2004·European Journal of Pharmacology·Shaun JordanC Anthony Altar
Feb 18, 2004·Current Medicinal Chemistry·M L CarlssonM Nilsson
Feb 20, 2004·The International Journal of Neuropsychopharmacology·Anissa Abi-Dargham
May 26, 2005·Progress in Neuro-psychopharmacology & Biological Psychiatry·Johan P RungMaria L Carlsson

❮ Previous
Next ❯

Citations

May 3, 2011·Naunyn-Schmiedeberg's Archives of Pharmacology·Johan P RungMaria L Carlsson
Mar 9, 2012·European Journal of Clinical Pharmacology·A HelldénL Bertilsson
Aug 30, 2011·Journal of Neural Transmission·Maria L CarlssonArvid Carlsson
Sep 25, 2014·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Nelleke TolboomArvid Carlsson
May 13, 2014·Journal of Neural Transmission·Susanna WatersNicholas Waters
Mar 10, 2009·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Faïza BenaliouadPierre-Paul Rompré
May 31, 2008·Brain Research Reviews·Arvid Carlsson, Maria L Carlsson
Feb 18, 2016·Expert Opinion on Investigational Drugs·Kathleen M Shannon
Jul 13, 2013·Movement Disorders : Official Journal of the Movement Disorder Society·Ralf Reilmann
Mar 17, 2015·Expert Review of Neurotherapeutics·Laetitia C SchwabRoger A Barker
Jan 13, 2015·Parkinsonism & Related Disorders·Daniel ZielonkaG Bernhard Landwehrmeyer
Dec 13, 2006·European Journal of Pharmacology·Philip Seeman, Hong-Chang Guan
Aug 23, 2018·Acta Neurologica Scandinavica·Sara HaghighiCarl-Gerhard Gottfries
Jan 7, 2020·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Ida FredrikssonYavin Shaham
Feb 27, 2018·Journal of Huntington's Disease·Susanna WatersNicholas Waters
Apr 28, 2017·British Journal of Clinical Pharmacology·Laura Rabinovich-GuilattOfer Spiegelstein
Sep 13, 2017·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Kristin FeltmannJohan Alsiö
Apr 26, 2018·Frontiers in Pharmacology·Kristoffer SahlholmFrancisco Ciruela
Apr 25, 2018·Naunyn-Schmiedeberg's Archives of Pharmacology·Vívian T da SilveiraFabrício A Moreira
Jan 21, 2021·Naunyn-Schmiedeberg's Archives of Pharmacology·Laila AsthFabrício A Moreira
Jul 15, 2021·Pharmacological Reviews·Ida FredrikssonYavin Shaham
Aug 6, 2021·Behavioural Brain Research·Gary RemingtonOfer Agid

❮ Previous
Next ❯

Related Concepts

Related Feeds

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here